Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

被引:442
作者
van Beek, E
Pieterman, E
Cohen, L
Löwik, C
Papapoulos, S
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2333 ZA Leiden, Netherlands
[2] TNO Prevent & Hlth, Gaubius Lab, Leiden, Netherlands
关键词
D O I
10.1006/bbrc.1999.1499
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bisphosphonates (Bps), inhibitors of osteoclastic bone resorption, are used in the treatment of skeletal disorders. Recent evidence indicated that farnesyl pyrophosphate (FPP) synthase and/or isopentenyl pyrophosphate (IPP) isomerase is the intracellular target(s) of bisphosphonate action. To examine which enzyme is specifically affected, we determined the effect of different Bps on incorporation of [C-14]mevalonate(MVA), [C-14]IPP, and [C-14]dimethylallyl pyrophosphate (DMAPP) into polyisoprenyl pyrophosphates in a homogenate of bovine brain. HPLC analysis revealed that the three intermediates were incorporated into FPP and geranylgeranyl pyrophosphate (GGPP). In contrast to clodronate, the nitrogen-containing Bps (NBps), alendronate, risedronate, olpadronate, and ibandronate, completely blocked FPP and GGPP formation and induced in incubations with [C-14]MVA a 3- to 5-fold increase in incorporation of label into IPP and/or DMAPP. Using a method that could distinguish DMAPP from IPP on basis of their difference in stability in acid, we found that none of the NBps affected the conversion of [C-14]TPP into DMAPP, catalyzed by IPP isomerase, excluding this enzyme as target of NBp action. On the basis of these and our previous findings, we conclude that none of the enzymes up- or downstream of FPP synthase are affected by NBps, and FPP synthase is, therefore, the exclusive molecular target of NBp action. (C) 1999 Academic Press.
引用
收藏
页码:108 / 111
页数:4
相关论文
共 13 条
[1]  
AMIN D, 1992, J LIPID RES, V33, P1657
[2]  
BARNARD GF, 1985, METHOD ENZYMOL, V110, P155
[3]   Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [J].
Fisher, JE ;
Rogers, MJ ;
Halasy, JM ;
Luckman, SP ;
Hughes, DE ;
Masarachia, PJ ;
Wesolowski, G ;
Russell, RGG ;
Rodan, GA ;
Reszka, AA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :133-138
[4]   Bisphosphonates: Mechanisms of action [J].
Fleisch, H .
ENDOCRINE REVIEWS, 1998, 19 (01) :80-100
[5]  
Kanis JK., 1994, BONE MINERAL RES, P265
[6]   Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras [J].
Luckman, SP ;
Hughes, DE ;
Coxon, FP ;
Russell, RGG ;
Rogers, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :581-589
[7]   PROCEDURES FOR THE ISOLATION AND QUANTIFICATION OF THE INTERMEDIATES OF THE MEVALONIC ACID PATHWAY [J].
MCCASKILL, D ;
CROTEAU, R .
ANALYTICAL BIOCHEMISTRY, 1993, 215 (01) :142-149
[8]   Mechanisms of action of bisphosphonates [J].
Rodan, GA .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 :375-388
[9]   Molecular mechanisms of action of bisphosphonates [J].
Rogers, MJ ;
Frith, JC ;
Luckman, SP ;
Coxon, FP ;
Benford, HL ;
Mönkkönen, J ;
Auriola, S ;
Chilton, KM ;
Russell, RGG .
BONE, 1999, 24 (05) :73S-79S
[10]  
SLAKEY LL, 1972, J BIOL CHEM, V247, P3014